LAMP Tech Advantages  For Investors  Clinical Results

LAMP-Vax™, a new approach to DNA vaccines - Competitive Advantages

A brief company update for investors


Impressive Clinical Results from our Phase IA & IB Studies

FEATURED NEWS
Immunomic Therapeutics Announces Significant Strides in Peanut Allergy Vaccine Development
This is an exciting development that may finally lead to a product to treat peanut allergy and eliminate the daily fear and unintended consequences of accidental exposure,” said Dr. Teri Heiland, ITI’s Vice President of Research and Development. “So many children are just a bite away from a potentially deadly allergic reaction. The world needs a solution, and completion of this study and external validation of the product puts us right on the doorstep of clinical validation of this breakthrough treatment
Click for Press Release on 06/17/2014
Immunomic Therapeutics Announces Significant Strides in Peanut Allergy Vaccine Development

COMPANY
TECHNOLOGY
CLINICAL
MEDIA
Immunomic Therapeutics, Inc.
Headquarters: 1214 Research Blvd, Suite 2016, Hershey, PA 17036
Phone: 717-327-1919
Lab: 15010 Broschart Rd. Ste. 250, Rockville, MD 20850
Phone: 866-515-9484

© 2007-2013 Immunomic Therapeutics, Inc.
All rights reserved
by: Design Media Land, LLC